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Do ethnicity, degree of family relationship,
and the spondyloarthritis subtype in
affected relatives influence the association
between a positive family history for
spondyloarthritis and HLA-B27 carriership?
Results from the worldwide ASAS cohort
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Abstract
Background: The Assessment of SpondyloArthritis international Society (ASAS) defines a positive family history (PFH)
of spondyloarthritis (SpA) as the presence of ankylosing spondylitis (AS), acute anterior uveitis (AAU), reactive arthritis
(ReA), inflammatory bowel disease (IBD), and/or psoriasis in first-degree relatives (FDR) or second-degree relatives (SDR).
In two European cohorts, a PFH of AS and AAU, but not other subtypes, was associated with human leukocyte antigen
B27 (HLA-B27) carriership in patients suspected of axial SpA (axSpA). Because the importance of ethnicity or degree of
family relationship is unknown, we investigated the influence of ethnicity, FDR, or SDR on the association between a
PFH and HLA-B27 carriership in patients suspected of axSpA.
Methods: Baseline data from the ASAS cohort of patients suspected of axSpA were analyzed. Univariable analyses were
performed. Each disease (AS, AAU, psoriasis, IBD, ReA) in a PFH according to the ASAS definition was a determinant in
separate models with HLA-B27 carriership as outcome. Analyses were stratified for self-reported ethnicity, FDR, and SDR.
Analyses were repeated in multivariable models to investigate independent associations.
Results: A total of 594 patients were analyzed (mean [SD] age 33.7 [11.7] years; 46% male; 52% HLA-B27+; 59% white,
36% Asian, 5% other). A PFH was associated with HLA-B27 carriership in patients with a white (OR, 2.3, 95% CI, 1.4–3.9)
or Asian ethnicity (OR, 3.1, 95% CI, 1.6–5.8) and with a PFH in FDR (OR, 2.9, 95% CI, 1.8–4.5), but not with a PFH in SDR
(OR, 1.7, 95% CI, 0.7–3.8) or in other ethnicities. A PFH of AS was positively associated with HLA-B27 carriership in all
subgroups (white OR, 7.1; 95% CI, 2.9–17.1; Asian OR, 5.7; 95% CI, 2.5–13.2; FDR OR, 7.8; 95% CI, 3.8–16.0; SDR OR, 3.7;
95% CI, 1.2–11.6). A PFH of AAU, ReA, IBD, or psoriasis was never positively associated with HLA-B27 carriership. In the
multivariate analysis, similar results were found.
Conclusions: In the ASAS cohort, a PFH of AS, but not of AAU, ReA, IBD, or psoriasis, was associated with HLA-B27
carriership regardless of white or Asian ethnicity or degree of family relationship. This cohort and two European cohorts
show that a PFH of AS and possibly a PFH of AAU can be used to identify patients who are more likely to be HLA-B27-
positive and therefore may have an increased risk of axSpA.
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Background
Axial spondyloarthritis (axSpA) is a chronic inflammatory
disease that causes inflammation mainly in the sacroiliac
joints (SI) and spine [1]. In patients with ankylosing spon-
dylitis (AS), also termed radiographic axSpA, susceptibility
is thought to be largely genetically determined, and the
strongest known genetic risk factor for axSpA is human
leukocyte antigen B27 (HLA-B27) [1, 2]. Different
prevalence rates of axSpA are reported across geogra-
phical regions, which have been related to the varying
prevalence of HLA-B27 worldwide [3]. A family history of
spondyloarthritis (SpA) is common in patients with AS
[4], and HLA-B27-positive first-degree relatives of
HLA-B27-positive patients with AS are 16 times more
likely to develop AS than HLA-B27-positive individuals in
the general population [5]. Additionally, several studies
have shown that first-degree relatives of a patient with AS
have a higher risk of developing AS than second-degree
relatives [6–8]. Therefore, a positive family history
(PFH) of SpA, and in particular a PFH in first-degree
relatives of patients with SpA, is thought to be a risk
factor of axSpA in patients with chronic back pain
(CBP), and a PFH of SpA is a component of several
SpA classification criteria [9, 10].
The Assessment of SpondyloArthritis international
Society (ASAS) defined, by consensus, a PFH of AS, acute
anterior uveitis (AAU), reactive arthritis (ReA), inflamma-
tory bowel disease (IBD), and/or psoriasis in first- or
second-degree relatives as an SpA feature in the ASAS clas-
sification criteria for axSpA [11]. Because a PFH of SpA is
thought to increase the risk for axSpA in patients with CBP,
it has been incorporated into several referral strategies for
patients with CBP suspected of axSpA [12, 13].
So far, only one study has investigated the performance
of the definition of a PFH in identifying patients with an
increased risk for axSpA. Ez-Zaitouni et al. reported that
in two cohorts predominantly Caucasian CBP patients
suspected of axSpA, a PFH for AS and AAU was positively
associated with HLA-B27 carriership. A PFH for ReA,
IBD, or psoriasis was not associated with HLA-B27 car-
riership and did not point to HLA-B27 carriership in pa-
tients with back pain [14]. Unfortunately, this study did
not to distinguish between first- or second-degree rela-
tives, and therefore it was unclear if a distinction in a PFH
in first- or second-degree relatives matters. Moreover, be-
cause the study was performed in two European cohorts,
it was unclear if the authors’ findings are relevant to popu-
lations outside Europe.
The ASAS cohort provides a unique opportunity to
study the performance of the current ASAS definition of a
PFH in patients of different ethnicities who have CBP and
are suspected of axSpA [11, 15, 16]. Therefore, we investi-
gated in this international cohort the impact of ethnicity
and degree of family relationship on the association
between the current ASAS definition of a PFH and the
presence of HLA-B27 in patients suspected of axSpA.
Methods
The ASAS cohort is an international cohort that includes
patients with a suspicion of axSpA (> 3 months of back
pain, age at onset < 45 years, with or without peripheral
symptoms) or peripheral SpA (pSpA; current peripheral
arthritis and/or dactylitis and/or enthesitis but without
current CBP) [11, 15, 16]. Worldwide, 975 patients were
included by 29 ASAS centers between November 2005
and January 2009. Patients were included in a consecutive
manner, including all eligible patients or every first to
third eligible patient per day. Local ethical committees ap-
proved the study, and informed consent was obtained
from all study participants before inclusion [11, 15, 16].
Data collection
At baseline, clinical, laboratory, and imaging data were
collected from all patients, including HLA-B27 carriership
and radiography of the SI. Magnetic resonance imaging of
the SI (MRI-SI) was considered obligatory for the first 20
patients of each center. Patients were diagnosed by the
treating rheumatologist, and for each patient, the level of
confidence regarding the diagnosis on an 11-point nume-
rical rating scale from 0 (not confident at all) to 10 (very
confident) was provided. For the current analysis, only
patients with a certain diagnosis of axSpA or no axSpA
(confidence level ≥ 6) were analyzed.
In addition, patients were asked to report their ethnicity
using an open-ended question. Self-reported ethnicities
were white, Asian, black, East Indian, Hispanic/Latino,
mixed, and Turkish. The self-reported ethnicities were
reclassified into white, Asian, and other ethnicities
(Hispanic/Latino n = 11, black n = 7, mixed n = 4, Turkish
n = 3, East Indian n = 2, unknown = 5).
The ASAS expert definition was used to assess if patients
had a PFH of SpA (ASAS PFH) (i.e., the presence of AS,
AAU, psoriasis, IBD, and/or ReA in first- or second-degree
relatives) [11]. Patients were asked to report if any family
history disease was present in a relative and in which rela-
tive(s). In the ASAS expert definition, father, mother, sister,
brother, daughter, and son are defined as first-degree rela-
tives and grandmother, grandfather, aunt, uncle, niece, and
nephew as second-degree relatives [11]. Furthermore, in
addition to the ASAS definition, granddaughter, grandson,
half-sister, and half-brother were also considered to be
second-degree relatives.
Data analysis
Baseline data were analyzed. Continuous variables were
presented as mean and SD and categorical variables as
frequencies (proportions). Univariable logistic models,
stratified by self-reported ethnicity or degree of family
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relationship (a PFH in first- or only second-degree rela-
tives), were used to assess the association between each
disease (AS, AAU, ReA, IBD, psoriasis) in a PFH and
HLA-B27 carriership. The analyses were repeated in
multivariable logistic models to investigate if each family
history disease was associated, independently of other
PFH subtypes, with HLA-B27 carriership. Patients with
a PFH in both first- and second-degree relatives were
classified into the group of patients with PFH in a
first-degree relative (n = 11) for both the univariable and
multivariable analyses. STATA SE version 14 software
(StataCorp, College Station, TX, USA) was used to
perform data analyses.
Results
In the ASAS cohort, 642 patients were diagnosed with a
confidence level ≥ 6 as axSpA or no axSpA. Patients
were excluded from the analysis if the family history was
missing (n = 48). For the current analysis, 594 patients
were used. Patients had a mean age (SD) of 33.7 (11.7)
years, and 46% were male. Mean symptom duration was
7.1 (9.0) years, and a mean of 2.4 (1.6) SpA features, ex-
cluding HLA-B27 and imaging, were present. Of the
sample, 52% were HLA-B27-positive, 20% had radio-
graphic sacroiliitis, and 45% had active inflammation by
MRI-SI (Table 1). Sixty-two percent of the patients were
diagnosed as axSpA.
In total, 59% of patients reported to be white, 36% to
be Asian, and 5% reported another ethnicity (Table 1).
An ASAS PFH was reported by 23% of the patients; a
PFH of AS was the most frequently reported family
Table 1 Baseline characteristics of chronic back pain patients
suspected of axial spondyloarthritis included in the ASAS cohort
Characteristics Data (N = 594)
Age at baseline, years 33.7 (11.7)
Male sex 276 (46%)





IBP (according to experts’ definition) 301/532 (57%)
Good response to NSAIDsc 274 (46%)






Positive family history according to ASAS definition 135 (23%)
Positive family history of AS 87 (15%)
Positive family history of AAU 7 (1%)
Positive family history of ReA 8 (1%)
Positive family history of IBD 12 (2%)
Positive family history of Psoriasis 36 (6%)
Total number of SpA-related diseases in first- or second-degree relatives
Number of patients with one disease 120 (20%)
Number of patients with two diseases 15 (3%)
Total number of family members with SpA-related diseases
Number of patients with one relative 102 (17%)
Number of patients with two relatives 30 (5%)
Number of patients with three relatives 3 (1%)
Total number of patients with positive family history in
First-degree relatives only 100 (17%)
Second-degree relatives only 25 (4%)
Both first- and second-degree relatives 10 (2%)
HLA-B27 positivity 310 (52%)
Elevated CRP/ESR 185 (31%)
Definite radiographic sacroiliitise 119/593 (20%)
Presence of active inflammation on MRI-SI 189/424 (45%)
Table 1 Baseline characteristics of chronic back pain patients
suspected of axial spondyloarthritis included in the ASAS cohort
(Continued)
Characteristics Data (N = 594)
Number of SpA featuresf,g 2.4 (1.6)
Clinical diagnosis of axSpAh 368 (62%)
Abbreviations: AAU Acute anterior uveitis, AS Ankylosing spondylitis, ASAS
Assessment of SpondyloArthritis international Society, (ax)SpA (Axial)
spondyloarthritis, CRP C-reactive protein, ESR Erythrocyte sedimentation rate,
HLA-B27 Human leukocyte antigen B27, IBD Inflammatory bowel disease, IBP
Inflammatory back pain, MRI-SI Magnetic resonance imaging of the sacroiliac
joints, NSAID Nonsteroidal anti-inflammatory drug, ReA Reactive arthritis, SI
Sacroiliac joint
Results are presented as mean ± SD unless specified otherwise
a < 5% missing values
b Self-reported ethnicity was missing for five patients, who are included in this
category, and other self-reported ethnicities are black, East Indian, Hispanic/
Latino, mixed, or Turkish
c Back pain not present anymore or is much better 24–48 hours after a full
dose of NSAID
d Past or present condition
e Grade ≥ 2 bilateral or grade ≥ 3 unilateral
f Excluding HLA-B27 carriership and imaging
g < 20% missing values
h Level of confidence regarding the diagnosis is ≥ 6
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history, with 15% (64% of all PFH), and a PFH of AAU
was the least often reported, with 1% (5% of all PFH),
among all patients (Table 1). An ASAS PFH in
first-degree relatives only was reported in 17% of pa-
tients, in second-degree relatives in 4%, and in both first-
and second-degree relatives in 2% of the patients.
An ASAS PFH and a PFH of AS were positively asso-
ciated with HLA-B27 in all patients suspected of axSpA
(ASAS PFH OR, 2.6; 95% CI, 1.7–3.9; PFH of AS OR,
6.5; 95% CI, 3.5–12.1). When these patients were strati-
fied according to ethnicity and degree of family relation-
ship, positive associations were found between an ASAS
PFH and HLA-B27 carriership in patients with a
self-reported white (OR, 2.3; 95% CI, 1.4–3.9) or Asian
ethnicity (OR, 3.1; 95% CI, 1.6–5.8) and with a PFH in
first-degree relatives (OR, 2.9; 95% CI, 1.8–4.5), but not
in second-degree relatives (OR, 1.7; 95% CI, 0.7–3.8)
(Table 2). A PFH of AS was positively associated with
Table 2 Univariable associations between a positive family
history and HLA-B27 carriership in patients suspected of axial








Positive family history according to ASAS definition
Stratified by self-reported ethnicity
White 54 26 2.3
(1.4–3.9)
0.001
Asian 38 14 3.1
(1.6–5.8)
0.001
Other ethnicitiesa 2 1 2.3
(0.2–25.0)
0.509











Positive family history of AS
Stratified by self-reported ethnicity
White 37 6 7.1
(2.9–17.1)
< 0.001
Asian 35 7 5.7
(2.5–13.2)
< 0.001
Other ethnicitiesa 2 0 n.a. n.a.











Positive family history of AAU
Stratified by self-reported ethnicity
White 4 0 n.a. n.a.
Asian 2 1 1.9
(0.2–20.7)
0.613
Other ethnicitiesa 0 0 n.a. n.a.








1 0 n.a. n.a.
Positive family history of ReA
Stratified by self-reported ethnicity
White 2 2 0.9
(0.1–6.5)
0.924
Asian 1 3 0.3
(0.03–2.9)
0.302
Other ethnicitiesa 0 0 n.a. n.a.








0 3 n.a n.a
Table 2 Univariable associations between a positive family
history and HLA-B27 carriership in patients suspected of axial








Positive family history of IBD
Stratified by self-reported ethnicity
White 2 7 0.3
(0.05–1.2)
0.089
Asian 0 2 n.a. n.a.
Other ethnicitiesa 0 1 n.a. n.a.
Stratified by degree of family relationship








Positive family history of psoriasis
Stratified by self-reported ethnicity
White 16 15 1.0
(0.5–2.0)
0.938
Asian 2 2 0.9
(0.1–6.5)
0.926
Other ethnicitiesa 0 1 n.a. n.a.
Stratified by degree of family relationship








Statistically significant results are printed in bold
Abbreviations: AAU Acute anterior uveitis, AS Ankylosing spondylitis, HLA-B27
Human leukocyte antigen B27, IBD Inflammatory bowel disease, n.a. Not
applicable, ReA Reactive arthritis
aSelf-reported ethnicities was missing for five patients, who are included in
this category, and other ethnicities are black, East Indian, Hispanic/Latino,
mixed, or Turkish
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HLA-B27 carriership in all subgroups (white OR, 7.1;
95% CI, 2.9–17.1; Asian OR, 5.7; 95% CI, 2.5–13.2;
first-degree relatives OR, 7.8; 95% CI, 3.8–16.0;
second-degree relatives OR, 3.7; 95% CI, 1.2–11.6). A
PFH of AAU, ReA, IBD, or psoriasis was not positively
associated with HLA-B27 carriership in patients
suspected of axSpA, regardless of the degree of family
relationship or ethnicity (Table 2). In the multivariable
analysis, similar results were found (data not shown).
Discussion
In patients suspected of axSpA in the worldwide ASAS
cohort, a PFH of AS was the predominant PFH subtype
and was associated, independently of other PFH subtypes,
with HLA-B27 carriership, regardless of self-reported
ethnicity or degree of family relationship. No positive as-
sociations were found between a PFH of AAU, ReA, IBD,
or psoriasis and HLA-B27 carriership. However, it should
be noted that in patients with CBP suspected of axSpA, a
PFH of AAU, ReA, and IBD was less common than a PFH
of AS, which is in line with previous studies. Somewhat
stronger associations were found for patients with white
ethnicity and for patients with a PFH in first-degree rela-
tives. Nonetheless, a PFH of AS was strongly associated
with HLA-B27 carriership in both white and Asian
patients and in both first- and second-degree relatives.
Our study is in line with the study of Ez-Zaitouni et al.
in two European cohorts because they reported that a
PFH of AS is associated with HLA-B27 carriership, but a
PFH of ReA, IBD, or psoriasis was not [14]. In this
study, a PFH of ReA, IBD, and AAU was also less com-
mon than a PHF of AS. However, in contrast to our
findings, Ez-Zaitouni et al. [14] also found that a PFH of
AAU contributed to the identification of axSpA because
this was associated with HLA-B27 carriership in patients
with CBP. In our study, a PFH of AAU was rarely re-
ported (1%), as compared with 5–6% in the study of
Ez-Zaitouni et al., which may limit detecting a possible
association with HLA-B27 carriership owing to sample
size. We have no proper explanation why a PFH of AAU
was less common in our study. It may be attributed to
differences in ethnicity (European cohorts vs. worldwide
cohort in our study). However, the frequency of a PFH
of AAU was similarly low in white and Asian patients in
our cohort (0.7% vs. 0.5%). Moreover, the frequency of
AAU in patients suspected of axSpA was similar in our
cohort (9% overall; 10% in white and 6% in Asian patients)
as compared with 8% in the study by Ez-Zaitouni et al.
In a general practice setting or other low SpA preva-
lence settings, a PFH of AS could be used for identifying
HLA-B27-positive patients among patients suspected of
axSpA. The RADAR study showed that HLA-B27 is a
good referral tool for identifying patients with axSpA,
because HLA-B27 has a higher sensitivity than an ASAS
PFH [17]. Therefore, it is recommended that a PFH of
AS should be used as a criterion for referral to secon-
dary care only when HLA-B27 testing is not feasible.
The current study investigated patients with axial
symptoms (i.e., patients with CBP suspected of axSpA)
of the ASAS cohort, and therefore it is important to
emphasize that the results are not applicable to patients
with predominantly peripheral symptoms. In patients
with predominantly peripheral symptoms, a PFH of, for
example, psoriasis could be important and relevant for
identifying patients with an increased risk of pSpA [15].
An important strength of this study is that the ASAS
study is a worldwide cohort, which enabled us to investi-
gate different self-reported ethnicities. Another strength is
the availability of extensive information on family history,
which allowed us to investigate the role of first- and
second-degree relatives for each manifestation of a PFH.
A major limitation is the self-reported family history by
patients. This could lead either to an underestimation if a
patient forgets or is unaware that a relative has an
SpA-related disease or to an overestimation if a patient is
confused or mistaken in the type of disease of a relative.
Nevertheless, in a clinical setting, the physician usually
has to depend on patient-reported family history. Another
limitation is the small percentage of patients with
self-reported ethnicity other than being white or Asian.
Only 5% of the patients reported to be Hispanic/Latino,
black, mixed, Turkish, East Indian, or unknown ethnicity.
Therefore, the results are applicable only to white or Asian
populations, which corresponds to the largest population
with axSpA worldwide [18]. Preferably, future research
into the value of a PFH for identifying HLA-B27 carrier-
ship should be conducted in patients with other ethnici-
ties. In this study, we focused on the use of a PFH of SpA
for identifying patients with CBP who are at an increased
risk of HLA-B27 carriership, but we did not investigate
the potential added value of a PFH in diagnosing patients
with axSpA. We are currently analyzing data from three
independent axSpA cohorts to address this issue.
Conclusions
Our data, in combination with data from two European
cohorts, show that a PFH of AS and possibly also a PFH
of AAU, regardless of ethnicity (white or Asian) or
degree of family relationship, is valuable for identifying
patients with CBP who could be HLA-B27-positive and
consequently have an increased risk of axSpA.
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